 <h1>Denileukin diftitox Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to denileukin diftitox: parenteral injection concentrate</i></p><h3>Warning</h3><p><ul>
<li>
Administer only under supervision of qualified clinicians experienced in use of cytotoxic therapy.&lt;sup&gt;1&lt;/sup&gt;</li></ul></p><ul>
<li>
Administer only under supervision of qualified clinicians experienced in use of cytotoxic therapy.&lt;sup&gt;1&lt;/sup&gt;</li></ul><p>
<li>
Closely monitor patients in a setting equipped and staffed by health-care personnel appropriately trained in CPR.&lt;sup&gt;1&lt;/sup&gt;</li></p><p></p><p>Side effects include:</p><p>Hypoalbuminemia, chills/fever, asthenia, infection, chest pain, hypotension, vasodilation, edema, dyspnea, nausea/vomiting, anorexia, diarrhea, anemia, increase in serum aminotransferase concentrations, dizziness, pain, headache, cough, rash, pruritus.   </p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to denileukin diftitox: intravenous solution</i></p><h3>Other</h3><p><b>Very common</b> (10% or more): Infusion reactions (up to 70.5%), pyrexia (up to 63.6%), rigors (up to 47.3%), fatigue (up to 46.7%), peripheral edema (up to 25.5%), asthenia (up to 18.2%), pain (up to 12.7%), chest pain (up to 12.7%)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Capillary leak syndrome (up to 32.5%), hypotension (up to 16.4%)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Visual changes (e.g., visual acuity loss)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (up to 24.4%), pruritus (up to 18.2%)<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Postmarketing reports</b>: Thyroid conditions (hyperthyroidism, thyroiditis, thyrotoxicosis, and hypothyroidism)</p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 60%), vomiting (up to 34.5%), diarrhea (up to 22.2%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased ALT or increased AST (up to 84%)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Anorexia (up to 20%)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Myalgia (up to 20%), back pain (up to 18.2%), arthralgia (up to 15.6%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 28.9%), dizziness (up to 12.7%), dysgeusia (up to 10.9%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (up to 20%), upper respiratory tract infection (up to 13.3%), dyspnea (up to 13.3%)<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Ontak (denileukin diftitox)." Ligand Pharmaceuticals, San Diego, CA. </p><h2>More about denileukin diftitox</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: miscellaneous antineoplastics</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Lymphoma</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>